-
2023-507582-25-00
5
2019-08-02
Malignant Extracranial Germ Cell Tumours (MGCT)
-
2023-509216-28-00
4
2019-05-27
Generalized Pustular Psoriasis
-
2022-502832-37-00
5
2019-03-01
Acute myeloid leukemia
-
2023-509602-29-00
5
2019-02-11
Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)
-
2024-515783-31-00
5
2018-08-24
Newly Diagnosed Multiple Myeloma
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-505509-18-00
5
2017-07-12
mature aggressive B-cell lymphoma and leukemia in children and adolesc
-
2023-505981-26-00
5
2015-11-20
Non−Small Cell Lung Cancer
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2024-514051-15-00
7
2023-07-10
Adult patients with relapsed or refractory IDH1-mutated AML or relapse
-
2024-511708-18-00
4
2022-12-06
Locally advanced or metastatic KRAS G12C-mutated non-small cell lung c
-
2024-510972-19-00
4
2025-03-13
Primary mediastinal large B-cell lymphoma (PMBCL)
-
2023-508959-39-00
5
2025-02-20
Moderate to Severe Plaque Psoriasis
-
2024-511360-87-00
5
2024-10-02
hidradenitis suppurativa (HS)
-
2023-508377-82-00
10
2024-06-27
Hidradenitis Suppurativa (HS)
-
2023-505841-22-00
5
2024-04-04
Moderate to Severe Plaque Psoriasis
-
2023-505558-16-00
5
2023-10-24
Atopic Dermatitis
-
2022-501074-19-00
10
2023-10-13
Hidradenitis suppurativa
-
2022-502837-24-00
5
2023-09-25
Overweight
-
2023-509746-35-00
4
2023-05-16
Primary Discoid Lupus Erythematosus
-
2022-500608-23-00
4
2023-04-06
Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squ
-
2024-516300-41-00
5
2023-03-07
Multiple Myeloma